An open-label, multicenter, three-stage, phase II study of S-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 8, 2011, Pages 1400-1406

  Sandler, Alan ^a   Graham, Charles ^b   Baggstrom, Maria ^c   Herbst, Roy ^d   Zergebel, Christopher ^e   Saito, Kaku ^e   Jones, Dennie ^f  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Charleston Cancer Center   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Taiho Pharma USA   (United States)

^f UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Cisplatin; Clinical trial; Fluoropyrimidines; Lung cancer; Non small cell; S 1

Indexed keywords

CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CONSTIPATION; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT;

EID: 80051781864     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31820d7805     Document Type: Article

References (36)

1. American Cancer Society. Cancer Facts & Figures 2009. Atlanta, GA: American Cancer Society; 2009. Available at: downloads/STT/500809web.pdf. Accessed October 17, 2009.
2. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550. (Pubitemid 44917502)
3. NCCN Clinical Practice Guidelines in Oncology: Non-small Cell Lung Cancer. National Comprehensive Cancer Network, V.2.2010. Available at: http://www.nccn.org/professionals/physician-gls/PDF/nscl.pdf. Accessed April 20, 2010.
4. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
5. Fukui Y, Oka T, Nagayama S, et al. Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int J Mol Med 2008;22:709-716.
6. Fukushima M, Morita M, Ikeda K, et al. Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors. Int J Mol Med 2003;12:839-844.
7. Yang CT, Chang WC, Chen LH, et al. Concurrent 5-fluorouracil, leucovorin, etoposide, cisplatin and radiotherapy for locally advanced non-small cell lung cancer. Changgeng Yi Xue Za Zhi 1997;20:187-194.
8. Ball D, Smith J, Bishop J, et al. A phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-smallcell lung cancer. Br J Cancer 1997;75:690-697. (Pubitemid 27091083)
9. Crawford J, O'Rourke M, Schiller JH, et al. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol 1996;14:2774-2784. (Pubitemid 26329664)
10. Nakano T, Ikegami H, Nakamura S, et al. A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group. Br J Cancer 1996;73:1096-1100. (Pubitemid 26131231)
11. Tanaka F, Yanagihara K, Ohtake Y, et al. p53 status predicts the efficacy of postoperative oral administration of tegafur (FT) for completely resected non-small cell lung cancer (NSCLC) (Meeting abstract). Proceedings of the Annual Meeting of the American Society of Clinical Oncology 1997;16:A1746.
12. Xu G, Rong T, Lin P. Adjuvant chemotherapy following radical surgery for non-small-cell lung cancer: a randomized study on 70 patients. Chin Med J (Engl) 2000;113:617-620. (Pubitemid 30622443)
13. Tanaka F, Miyahara R, Ohtake Y, et al. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg 1998;14:256-262. (Pubitemid 28417078)
14. Wada H, Hitomi S, Teramatsu T. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol 1996;14:1048-1054. (Pubitemid 26105508)
15. Wada H, Miyahara R, Tanaka F, et al. Postoperative adjuvant chemotherapy with PVM (Cisplatin- Vindesine- Mitomycin C) and UFT (Uracil- Tegafur) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG). Eur J Cardiothorac Surg 1999;15:438-443. (Pubitemid 29210345)
16. Sagar B, Estaphan F, Spell D.W, et al. A pilot phase II study of capecitabine with carboplatin in patients with advanced nonsmall cell lung cancer Int. J. Oncol. 2009 6-17
17. Shirasaka T, Shimamoto Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-557.
18. Tatsumi K, Fukushima M, Shirasaka T, et al. Inhibitory effect of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987;78:748-755. (Pubitemid 17132408)
19. Kawahara M, Furuse K, Segawa Y, et al; S-1 Cooperative Study Group (Lung Cancer Working Group). Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 2001;85:939-943.
20. Ichinose Y, Yoshimori K, Sakai H, et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 2004;10:7860-7864. (Pubitemid 39587524)
21. Ajani JA, Faust J, Ikeda K, et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 2005;23:6957-6965.
22. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10. (Pubitemid 19099520)
23. Sandler J, Nemunaitis J, Denham C, et al. Phase III study of cisplatin with or without gemcitabine in patients with advanced non-small cell lung cancer. J Clin Oncol 2000;18:122-130. (Pubitemid 30036345)
24. Okamoto I, Nishimura T, Miyazaki M, et al. Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: West Japan Thoracic Oncology Group 3505. Clin Cancer Res 2008;14:5250-5254.
25. Schiller JH, Harrington D, Belani CP, et al. Comparison of chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-98. (Pubitemid 34438899)
26. Kubota K, Sakai H, Yamamoto N, et al. A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010;5:702-706.
27. Satouchi M, Kotani Y, Katakami N, et al. Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naive patients with advanced non-small cell lung cancer. J Thorac Oncol 2010;5:696-701.
28. Thienelt CD, Bunn PA Jr, Hanna N, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005;23:8786-8793. (Pubitemid 46211524)
29. Millward MJ, Bishop JF, Friedlander M, et al. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 1996;14:142-148. (Pubitemid 26022464)
30. Zalcberg J, Millward M, Bishop J, et al. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J Clin Oncol 1998;16: 1948-1953.
31. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-2043. (Pubitemid 46622112)
32. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25:4743-4750. (Pubitemid 350086476)
33. Okabe T, Okamoto I, Tsukioka S, et al. Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced downregulation of thymidylate synthase. Mol Cancer Ther 2008;7:599-606. (Pubitemid 351492458)
34. Wada Y, Yoshida K, Suzuki T, et al. Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer 2006;119:783-791. (Pubitemid 44055889)
35. Lee J-H, Park J-H, Jung Y, et al. Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Mol Cancer Ther 2006;5:3085-3095. (Pubitemid 46092050)
36. Okamoto I, Fukuoka M. S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer. Clin Lung Cancer 2009;10:290-294.